Atropine Eye Drops for Myopia Control in Childhood —More Long-Term Data, Please

The Atropine Treatment Long-Term Assessment Study (ATLAS) has provided important very-long-term outcome data concerning the effectiveness and safety for prescribing various concentrations of atropine eye drops (0.01%, 0.1%, 0.5%, and 1.0%) for myopia control. The study findings affirm the importance of randomized short-term treatment trials complemented with long-term follow-up of participants whenever the medical condition being studied may continue to progress after stopping the intervention. In the instance of myopia control treatment, progression may be expected to continue for up to 2 decades after completing the randomized portion as well as the initial posttreatment observation portion of those trials.
Source: JAMA Ophthalmology - Category: Opthalmology Source Type: research